{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
dimethyl fumarate
to a specific field?
Status:
Investigational
Source:
NCT03418714: Phase 1/Phase 2 Interventional Completed Drug Effect
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Salvinorin A has been reported to be the most potent naturally occurring hallucinogen, with an effective dose in humans in the 200- to the 1,000-μg range when smoked; it has been reported to induce an intense hallucinatory experience in humans, with a typical duration of action being several minutes to an hour or so. Salvinorin A is a highly selective agonist of the kappa-opioid receptor (KOR) with few off-target effects. It is a potent and selective dilator of the cerebral vasculature, exhibits rapid penetration through the blood-brain barrier, has potent anti-inflammatory properties, and has the ability to preserve neurovascular unit integrity. As such, salvinorin A is an ideal compound for the prevention and treatment of cerebral vasospasm following subarachnoid hemorrhage.
Status:
Investigational
Source:
NCT00644488: Phase 1 Interventional Completed Prostate Cancer
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Bristol-Myers Squibb developed BMS-641988 as a nonsteroidal androgen receptor antagonist for the treatment of prostate cancer. BMS-641988 participated in phase I clinical trials in patients with castration-resistant prostate cancer in Japan and in the USA. However, further information is not available.
Status:
Investigational
Source:
NCT03292822: Phase 1 Interventional Completed Squamous Cell Carcinoma
(2021)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Licochalcone A (LicA) is a flavonoid isolated from the famous Chinese medicinal herb Glycyrrhiza uralensis Fisch and has a wide spectrum of pharmacological activities such as anti-oxidant, anti-bacterial, anti-viral, and anti-cancer. However, its pharmacological mechanism is not well defined. The anti-Inflammatory effects of LicA on IL-1β-Stimulated human osteoarthritis chondrocytes was reached by activating Nrf2 signaling pathway. LicA showed anti-proliferative and apoptotic effects in breast cancer cells through regulating Sp1 and apoptosis-related proteins in a dose- and a time-dependent manner. In addition, the chemotherapeutic potential of LicA for treatment of human cervical cancer was achieved by inhibition of PI3K/Akt/mTOR signaling.
Status:
Investigational
Source:
NCT01573819: Phase 1 Interventional Completed Huntington Disease
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
GlaxoSmithKline is developing GSK-356278 as a selective, brain-penetrant phosphodiesterase 4 (PDE4) inhibitor that demonstrates anxiolytic and cognition-enhancing effects. Small molecule phosphodiesterase (PDE) 4 inhibitors have long been known to show therapeutic benefit in various preclinical models of psychiatric and neurologic diseases because of their ability to elevate cAMP in various cell types of the central nervous system. The drug was studied for the treatment of Huntington's disease, depressive and anxiety disorders. GSK-356278 has completed phase I clinical trials for evaluation of the safety, tolerability, and pharmacokinetics in male volunteers with the therapeutic dose for future clinical development.
Status:
Investigational
Source:
Anesteziol Reanimatol. Sep 2017;61:224-227.: Not Applicable Human clinical trial Completed N/A
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT00972504: Phase 2 Interventional Completed Rhinitis, Allergic, Seasonal
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT01268527: Phase 2 Interventional Completed Psoriasis Vulgaris
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
E-6201 and discovered that the compound inhibits lipopolysaccharide-activated TNF-alpha reporter activity in THP-1-33 cells and selectively inhibits mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK)-1 and MEK kinase-1 in cell-free biochemical assays. In addition, E-6201 showed inhibitory activity in several other cell-based systems: 1) phosphorylation of c-jun N-terminal kinase and p38 MAPKs; 2) nuclear factor-kappaB and activated protein-1 activation in various cell types; 3) interleukin (IL)-2 production from human lymphocytes; 4) hyperproliferation of human keratinocytes; 5) IL-8 production from human keratinocytes; and 6) proinflammatory cytokine production from human peripheral blood mononuclear cells. Based on this data, E-6201 may be beneficial for treatment of inflammatory and hyperproliferative diseases such as psoriasis through its anti-inflammatory activities on immune cells and anti-hyperproliferative activities on keratinocytes. E-6201 exhibits anti-tumor efficacy against TNBC in vitro and anti-metastasis efficacy against triple-negative breast cancer in vivo.
Status:
Investigational
Source:
NCT03387410: Phase 1/Phase 2 Interventional Completed Ureter Injury
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT01852604: Phase 2 Interventional Completed Chronic Hepatitis C Virus
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
TMC647055 is a potent and selective nonnucleoside inhibitor of NS5B binding site 1 (NNI-1) with activity against most HCV genotypes. Binding of inhibitors to NNI-1 is purported to displace the flexible λ1 loop from its thumb domain binding site, perturbing the interaction between the NS5B polymerase finger and thumb domains and thereby locking the enzyme in an open inactive conformation. Janssen R&D Ireland (formerly Tibotec Pharmaceuticals) is developing TMC 647055 as an oral once-daily treatment for chronic hepatitis C virus infections. Phase II development is underway in Belgium, Germany and the US.
Status:
Investigational
Source:
NCT02993484: Not Applicable Interventional Completed Reperfusion Injuries, Myocardial
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
